The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2018 | Tabelecleucel for treating EBV associated PTLD
From the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA., Dietmar Berger, MD, PhD, of Atara Biotherapeutics, San Francisco, CA., outlines the focus on off-the-shelf, next-generation allogeneic T-cell immunotherapies including tabelecleucel for treating Epstein–Barr virus (EBV) associated post-transplant lymphoproliferative disorder (PTLD), which has received FDA breakthrough and EMA PRIME designation. Dr Berger also discusses the issues with current CAR T-cell therapy approaches and how by utilising novel co-stimulatory domains, can lead to prolonged response to CAR T-cell therapy.
